Anti-Ganglioside GD2 Recombinant Antibody (SAA0322) (YP115013)

Name: Anti-Ganglioside GD2 Recombinant Antibody (SAA0322)
Brand: abinScience
SKU: YP115013
Price: 126 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD): --

Spec:

20ug
50ug
100ug
1mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

YP115013

Description

Anti-Ganglioside GD2 Recombinant Antibody (SAA0322) (YP115013) is a human monoclonal antibody detecting Ganglioside GD2 in ELISA, IHC. Suitable for General.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.
●Multi-Application — Validated across multiple applications.

Species reactivity

General

Applications

ELISA, IHC

Host species

Human

Clonality

Monoclonal

Isotype

IgG1, kappa

Clone ID

SAA0322

Target

Ganglioside GD2

Endotoxin level

< 10 EU/mg as determined by LAL method.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

CAS: 65988-71-8

RRID

Anti-Ganglioside GD2 Antibody (SAA0322) (abinScience Cat# YP115013, RRID:AB_3725827)

Form

Liquid

Storage buffer

0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:2000-1:20000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Background

Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity.
• Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer., PMID:34596246
• GD2 is a Crucial Ganglioside in the Signal Modulation and Application as a Target of Cancer Therapeutics., PMID:39921214
• Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers., PMID:38593230
• Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma., PMID:39726234
• Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma., PMID:33479234
• Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins., PMID:35008849
• RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype., PMID:32486168
• Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M⁺ diffuse midline gliomas., PMID:29662203
• Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma., PMID:20879881

Note

For research use only.

Images

SDS-PAGE

SDS-PAGE for Anti-Ganglioside GD2 Antibody (SAA0322).

References

Datasheet

Anti-Ganglioside GD2 Recombinant Antibody (SAA0322).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Recombinant Proteins

Antibodies

Assay Kits

Anti-Ganglioside GD2 Recombinant Antibody (SAA0322) (YP115013)

Overview

Images

References

Datasheet

SDS